期刊文献+

阿托伐他汀对血脂正常患者心律失常的影响 被引量:1

下载PDF
导出
摘要 目的:通过临床调查分析他汀类药物(阿托伐他汀)在血脂正常患者心律失常临床治疗中的疗效,观察他汀类药物是否会产生副作用,从而指导临床应用他汀类药物。方法:选取120例血脂正常的心律失常患者随机分成对照组和观察组,对照组只接受常规药物(阿司匹林、硝酸酯类药)配合稳心颗粒治疗;观察组则在常规药物治疗的基础上每天加用阿托伐他汀10mg·d-1,对比两组患者的血脂变化情况与心律失常治疗情况。结果:经过治疗,观察组的血脂情况明显优于对照组,差异具有统计学意义(P<0.05);观察组的心律失常得到有效控制,明显优于对照组,差异具有统计学意义(P<0.05)。结论:阿托伐他汀能够有效控制心律失常患者的血脂变化,并且改善动脉粥样硬化,降低心血管事件的风险改善患者的心功能。
作者 赵国强
出处 《北方药学》 2014年第2期54-54,共1页 Journal of North Pharmacy
  • 相关文献

参考文献5

二级参考文献31

  • 1王振杰,田秀芝,李贤,陈祚,赵连成,周北凡,武阳丰,中国高胆固醇血症控制状况调查协作组.药物治疗的高胆固醇血症患者膳食治疗状况与血脂控制达标率——高胆固醇血症临床控制状况多中心协作研究[J].中华心血管病杂志,2005,33(4):372-375. 被引量:17
  • 2江平,何代平,许国旺.血浆辅酶Q_(10)的高效液相色谱快速测定[J].分析测试学报,2006,25(2):106-108. 被引量:7
  • 3李红霞,满永,国汉邦,唐蔚青,夏永静,董军,王抒,李健斋.北京市部分人群血压、血糖、血脂异常的知晓率、治疗率和达标率的调查[J].北京医学,2007,29(1):57-57. 被引量:17
  • 4He J,Gu D,Reynolds K,et al. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China[ J]. Circulation ,2004,110(4 ) :405 - 411.
  • 5Mataix J. Inhibition of LDL oxidation by ubiquinol-10 a pro tective mechanism for coenzyme Q in a therogensis[J]. Mol Aspects Med ,1997,18(Supplement) :85 103.
  • 6Rundek T, Naini A, Sacco R, et al . Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke[J]. Arch Neurol , 2004, 61 (6) : 889-892.
  • 7Lain, Hargreavel. The effect of HMG-CoA reductase inhibitor on coenzyme Q10 : possible biochemical/clinical implication[J].Drug Safety , 2005, 28(8):659-676.
  • 8Vasudevan AR, Hasmin YS, Jones PH. Safety of stains: effects on muscle and the liver[J]. Cleve Clin Med ,2005,72 (5) :996-1001.
  • 9Mabuchi H , Higashikata T, Kawashiri M, et al . Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients[J]. J Atheroscler Thromb , 2005, 12(2) :111-119.
  • 10Frederick L . Biochemical functions of coenzyme Q10 [J]. J Am Coll Nutr ,2001, 20(6) :591-598.

共引文献265

同被引文献25

  • 1曾毅.不同剂量辛伐他汀对高血压并高血脂患者内皮功能的影响[J].中国老年学杂志,2014,34(2):355-356. 被引量:35
  • 2Zhou Q, Liao JK. Pleiotropic effects of statins. -Basic research and clinical perspectives-[ J]. Circ J,2010,7d(5) :818-826.
  • 3Motayama K, Fukumoto S, Koyama H, et al. SREBP inhibits VEGF expression in human smooth muscle cells [ J ]. Biochem Biophys Res Commun,2006,342 ( 1 ) : 354-360.
  • 4Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothdial growth factor synthesis in endothelial and vascular smooth muscle cells [ J ]. Atherosclerosis ,2003,170 (2) :229-236.
  • 5Dichtl W, Dulak J, Frick M, et at. HMG-CoA reduetase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells [ J]. Arterioseler Thromb Vasc Biol, 2003,23 ( 1 ) :58-63.
  • 6Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors [J]. Cancer Res,2001,61 (12) :4885-4891.
  • 7Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease [ J ]. Neurology ,2007,69 (9) :878-885.
  • 8Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary resuhs [ J ]. Arch Neuro1,2005,62 ( 5 ) :753-757.
  • 9Htiglund K, Blennow K. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease [ J]. CNS Drugs,2007,21 (6) :449-462.
  • 10赵佼,董云霞.他汀类药物的临床应用及不良反应[J].实用药物与临床,2008,11(4):243-244. 被引量:33

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部